Immune booster vaccine shows promise against deadly brain cancer
NCT ID NCT02649582
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if this combination improves overall and progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dendritic cell vaccine plus temozolomide chemotherapy
- What this could lead to
- If it works, this could extend survival for people with newly diagnosed glioblastoma by boosting the immune system to fight the tumor.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply to everyone. The vaccine may not work or could cause side effects like inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antwerp University Hospital
Edegem, Antwerp, 2650, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?